{"id":"W2571616205","doi":"10.1182/blood.v120.21.2687.2687","title":"A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Radioimmunotherapy; Medicine; Diffuse large B-cell lymphoma; Internal medicine; Rituximab; Ibritumomab tiuxetan; Follicular lymphoma; CHOP; Oncology; Gastroenterology; Lymphoma; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002711286,0.001754587,0.001927612,0.0004970455,0.0004623789,0.001041899,0.001371706,0.0015476,0.003816585],"category_scores_gemma":[0.0009653782,0.0007811126,0.001457685,0.0005221216,0.001310647,0.001058972,0.0005163254,0.002969197,0.001025552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009432309,"about_ca_system_score_gemma":0.001560177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001308436,"about_ca_topic_score_gemma":0.002750034,"domain_scores_codex":[0.999409,0.0003333877,0.00002537459,0.00008247423,0.00003724808,0.0001125233],"domain_scores_gemma":[0.9992016,0.0001186943,0.0001307566,0.00007592684,0.00003998027,0.0004329927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8943134,0.06498052,0.003644277,0.0003814654,0.0006099922,0.0001315476,0.0002018149,0.001071101,0.009952243,0.0001464349,0.001519565,0.02304763],"study_design_scores_gemma":[0.6872108,0.3044284,0.006028164,0.00001793295,0.0002255872,0.00007128666,0.00004548072,0.0004024842,0.0005211739,0.00009981421,0.0009343649,0.00001457852],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924994,0.001031208,0.0003283001,0.0003526578,0.0001696521,0.00353442,0.0008351402,0.00006604827,0.001183158],"genre_scores_gemma":[0.9828121,0.001556054,0.00152202,0.001252428,0.000299386,0.006270169,0.002924291,0.00002911871,0.003334427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003816585,"threshold_uncertainty_score":0.01433879,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01081328882209624,"score_gpt":0.2910746114876294,"score_spread":0.2802613226655331,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}